Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aroplatin: AGEN began an open-label U.S. Phase II trial in patients with refractory metastatic colon cancer.

Antigenics Inc. (AGEN), New York,

Read the full 55 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE